Operational Stability in Preclinical Programs: Securing the NHP Model Supply Chain

The integrity of the data package for advanced therapeutics and complex biologics depends directly on the quality and availability of relevant models. For sponsors of next-generation therapies, applying proven intelligence in preclinical toxicology requires a secure, predictable supply chain to accelerate programs toward IND.

A colleague from the Bioculture Group noted that the value chain is diversifying. “We are no longer just dealing with a pill in a bottle. We are dealing with living cells, with viral vectors, and the infrastructure has to adapt to that reality.” This adaptation is most evident in the sourcing and management of nonhuman primate (NHP) models for pivotal toxicology and biodistribution assessments.

Selecting an NHP model with an immune system that closely mirrors the human response is a prerequisite for generating clinically relevant data. These models are necessary for characterizing potential liabilities before first-in-human administration.

• Preclinical safety evaluations can identify potential liabilities and characterize organ-specific toxicities following systemic vector administration (PMID: 38327046).
• Technical feasibility assessments using advanced imaging confirm that precise, real-time vector administration to specific anatomical targets is achievable, supporting direct clinical translation (PMID: 38310346).

A standard, one-size-fits-all preclinical testing template does not exist for these assets. A science-based strategy, tailored to the specific modality and target indication, is required. This strategy must account for the supply chain itself, where unforeseen delays in model availability or quarantine complications can add months to a program, jeopardizing timelines and financing.

To mitigate this risk, Franklin Biolabs maintains a strategic integration with the Bioculture Group. This provides our clients with a secure and transparent supply of Mauritian origin SPF cynomolgus macaques. The integrated supply chain includes U.S.-based quarantine and fully compliant regulatory import clearance, removing significant logistical burdens for U.S.-based biotech sponsors.

This operational stability ensures full traceability and access to well-characterized models for IND-enabling programs. It allows our scientific teams to focus on designing and executing the right toxicology programs to support a successful regulatory submission, moving therapeutic candidates toward IND within an 18-24 month timeframe.